Ultomiris 300 mg/3mL
ravulizumab · SOLUTION, CONCENTRATE · Alexion Pharmaceuticals Inc.
No Recall History
Plain English
Ultomiris is a solution, concentrate containing ravulizumab at 300 mg/3mL, taken intravenous. Manufactured by Alexion Pharmaceuticals Inc..
Key Facts
- Brand Name
- Ultomiris
- Generic Name
- ravulizumab
- NDC Code (Product)
25682-025- Manufacturer
- Alexion Pharmaceuticals Inc.
- Strength
- 300 mg/3mL
- Dosage Form
- SOLUTION, CONCENTRATE
- Route
- INTRAVENOUS
- Marketing Status
- Application #
- BLA761108
- Drug Class
- Complement Inhibitor [EPC]
- Marketing Start
- 10/09/2020
Recall History
No Recall HistoryFrequently Asked Questions
What is Ultomiris used for?
Ultomiris contains ravulizumab. It is a solution, concentrate taken intravenous. Consult your doctor for specific uses.
Is Ultomiris a controlled substance?
Ultomiris is not classified as a controlled substance by the DEA.
What is the generic name for Ultomiris?
The generic name for Ultomiris is ravulizumab. There are no other listed brand versions of ravulizumab.
What is the NDC code for Ultomiris 300 mg/3mL?
The NDC (National Drug Code) for Ultomiris 300 mg/3mL is 25682-025, listed by Alexion Pharmaceuticals Inc..
Other Ultomiris Dosages
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)